Breakthrough T1D Blog

Hero banner image

T1D Index

This blog contains content relating to early mortality due to Type 1 Diabetes, which may be confronting and distressing to some readers. Please exercise caution and care when engaging with this content.  How many people live with type 1 diabetes (T1D) around the globe?  How does T1D affect life expectancy?  How many lives could be […]

Honouring Peter Oliver’s life and legacy

September 23, 2022  JDRF is deeply saddened by the loss of an incredible individual who made an unparalleled impact at JDRF, Peter Oliver.   “Peter possessed a multitude of qualities that defined him as a leader – visionary, credible, trustworthy, respectful, influential, and empowering are just a few of these traits,” said Dave Prowten, President and CEO […]

Not all sugars are the same: Using glucose to treat hypoglycemia

The following is sponsored content developed in partnership with AMG Medical Low blood glucose—also known as hypoglycemia—can be one of the most challenging, stressful, and often scary parts of living with diabetes. Learning how to treat hypoglycemia is very important. If you live with type 1 diabetes (T1D), you know that being prepared for low […]

McGill University Health Centre designated provincial centre for islet transplantation for patients with type 1 diabetes

JDRF congratulates the McGill University Health Centre (MUHC) on its recent mandate to provide islet transplantation for persons with T1D in Quebec. This designation by Quebec’s Ministry of Health and Social Services recognizes the clinical and research teams at MUHC for their leadership and dedication in the field of islet transplantation. As one of only […]

COVID-19 Vaccine Approved by Health Canada now approved for kids six months to 5

Update: July 15, 2022 On Thursday, July 14, 2022 Health Canada approved the Moderna Spikevax Covid-19 vaccine for children aged six months to five years old. This makes approximately 1.7 million Canadian children eligible for vaccination. Health Canada has authorized a two-dose primary series of 25 micrograms each, with the second dose to be administered […]

Vertex Pharmaceuticals announces they have acquired ViaCyte

On Monday July 11, 2022, Vertex Pharmaceuticals announced they acquired ViaCyte for $320 million in cash to help speed up the development of VX-880, Vertex’s stem cell-derived therapy for people with type 1 diabetes (T1D). What does this mean for Canadians living with type 1 diabetes? T1D is an autoimmune disorder where the body destroys […]

Annual American Diabetes Association Conference showcases exciting developments in type 1 diabetes research

The American Diabetes Association’s 82nd Scientific Sessions, were held from June 3-7 both in person and virtually. This annual conference brings together researchers and scientists to both present and learn about the latest in type 1 diabetes research and technological advancements. Many of the presenters are funded by JDRF International, JDRF Canada’s affiliate in the […]

Back together again

The 2022 Sun Life Walk to Cure Diabetes for JDRF was a huge success! The Walk is the largest fundraising event in Canada to support type 1 diabetes (T1D) research. As a result of the pandemic, for the last two years, JDRF had to shift to a virtual event, and while our supporters still made […]

Sign up for our newsletter and stay connected

Receive the latest news and updates from Breakthrough T1D Canada

Help us create a world without type 1 diabetes

Give Now